Responses to Clonidine in Acute and Remitted Depressed Patients

  • L. J. Siever
  • E. F. Coccaro
  • F. Adan
  • R. C. Mohs
  • K. L. Davis
Conference paper


A variety of studies reporting abnormal hormone responses to noradrenergic challenges point toward the possibility that a blunted growth hormone response to clonidine, reflecting decreased a2-adrenergic responsiveness, may constitute a trait or vulnerability marker for depression. These results contrast with preliminary data suggesting greater state dependence of indices of noradrenergic output, such as concentrations of the noradrenergic metabolite 3-methoxy-4-hydroxy-phenylglycol (MHPG) and hormones such as cortisol in biologic fluids.


Growth Hormone Depressed Patient Growth Hormone Response Average Growth Hormone Vulnerability Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Annseau M, Scheyvaert M, Dumont A, Poirier R, Legros J-J, Frank G (1984) Concurrent use of REM latency, dexamethasone suppression, clonidine and apomorphine tests as a biological marker of endogenous depression: a pilot study. Psychiatry Res 12:261–272.CrossRefGoogle Scholar
  2. Blackard WG, Heidingsfelder SA (1968) Adrenergic receptor control mechanism for growth hormone secretion. J Clin Invest 47:1407–1414.PubMedCrossRefGoogle Scholar
  3. Carpenter WT, Bunney WE (1971) Adrenal cortical activity in depressive illness. Am J Psychiatry 128:63–72.Google Scholar
  4. Carroll BJ (1969) Hypothalamic-pituitary function in depressive illness insensitivity to hypoglycemia. Br Med J 111:27–28.CrossRefGoogle Scholar
  5. Carroll BJ (1972) Studies with hypothalamic-pituitary-adrenal stimulation tests in depression. In: Davis B, Barroll BJ, Mowbray RM (eds) Depressive illness: some research studies. C. C. Thomas, Springfield, pp 149–201.Google Scholar
  6. Carroll BJ, Curtis GC, Mendels J (1976) Neuroendocrine regulation in depression. I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry 33:1039–1044.PubMedGoogle Scholar
  7. Charney DS, Heninger GR, Sternberg DE, Roth RH (1981) Plasma MHPG in depression: effects of acute and chronic desipramine treatment. Psychiatry Res 5:2117–2129.CrossRefGoogle Scholar
  8. Charney DS, Heninger GR, Sternberg DE, Redmond DE, Leckman JE, Maas JW, Roth RH (1982a) Adrenergic receptor sensitivity in depression: effects of clonidine in depressed and healthy controls. Arch Gen Psychiatry 39:290–294.PubMedGoogle Scholar
  9. Charney DS, Heninger GR, Sternberg DE (1982b) Failure of antidepressant treatment to alter growth hormone response to clonidine. Psychiatry Res 17:135–138.CrossRefGoogle Scholar
  10. Checkley SA (1979) Corticosteroid and growth hormone responses to methylamphetamine in depressive illness. Psychol Med 9:107.PubMedCrossRefGoogle Scholar
  11. Checkley SA (1980) Neuroendocrine tests of monoamine function in man: a review of basic theory and its application to the study of depressive illness. Psychol Med 35-53.Google Scholar
  12. Checkley SA, Slade AP, Shur E (1981) Growth hormone and other responses to clonidine in patients with endogenous depression. Br J Psychiatry 138:51.Google Scholar
  13. Endo M, Endo J, Nishikubo M, Yamaguchi T, Hatotani N (1974) Endocrine studies in depression. In: Hatotani N (ed) Psychoneuroendocrinology. Workshop conference of the international society for psychoneuroendocrinology. S. Karger, Basel, pp 22–31.Google Scholar
  14. Gruen PH, Sachar EJ, Altman N, Sassin J (1975) Growth hormone responses to hypolycemia in post-menopausal depressed women. Arch Gen Psychiatry 32:31–33.PubMedGoogle Scholar
  15. Kathol RG, Sherman BM, Winokur G, Lewis D, Schlesser M (1983) Dexamathasone surpression, protirelin stimulation, and insulin infusion in subtypes of recovered depressive patients. Psychiatry Res 9:99–106.PubMedCrossRefGoogle Scholar
  16. Laakman G, Schumacher G, Benkert O, von Werder K (1977) Stimulation of growth hormone secretion by desimipramine and chlorpromazine in man. J Clin Endocr Metab 44:1010–1013.CrossRefGoogle Scholar
  17. Langer G, Heinze G, Reim B, Matussek N (1976) Reduced growth hormone responses to amphetamine in “endogenous” depressive patients: studies in normal, “reactive and endogenous” depressive, schizophrenic, and chronic alcoholic subjects. Arch Gen Psychiatry 33-1471.Google Scholar
  18. Lenox RH, Shipley JE, Peyser JM, Weaver LA, Armstrong CB, Astrikaga T (1983) Longitudinal neuroendocrine response in depression. New Research Abstracts of the American Psychiatric Association. NR 32.Google Scholar
  19. Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ (1982) Alteration of noradrenergic metabolism with desipramine and zimeldine in depressed patients. Arch Gen Psychiatry 39:1025–1032.PubMedGoogle Scholar
  20. Martin JB, Reichlin S, Brown GM (1977) Clinical neuroendocrinology. F. A. Davis, Philadelphia.Google Scholar
  21. Matussek N, Ackenheil M, Hippius H, Muller F, Schroder HT, Schultes H, Wasilewski B (1980) Effect of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res 2:25.PubMedCrossRefGoogle Scholar
  22. Mueller PS, Heninger GR, MacDonald R (1969) Insulin tolerance test in depression. Arch Gen Psychiatry 21:587.PubMedGoogle Scholar
  23. Pickar D, Sweeney DR, Maas JW (1978) Primary affective disorder, clinical state change and MHPG excretion: a longitudinal study. Arch Gen Psychiatry 35:1378–1388.PubMedGoogle Scholar
  24. Sachar EJ, Frantz AB, Altmann N, Sassin J (1973a) Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemina and L-dopa. Am J Psychiatry 130:1362.PubMedGoogle Scholar
  25. Sachar EJ, Hellman L, Roffwarg H, Halpern FS, Fukushima DK, Gallagher TE (1973b) Disrupted 24-hour patterns of cortisol secretion in psychotic depression. Arch Gen Psychiatry 28:19–25.PubMedGoogle Scholar
  26. Sachar EJ, Asnis G, Nathan RS, Halbreich U, Tabriz BA, Halpern FS (1981) Dextroamphetamine and cortisol on depression. Arch Gen Psychiatry 37:755.Google Scholar
  27. Siever LJ, Uhde TW (1984) New studies and perspectives on the noradrenergic receptor system in depression. Effects of the α2-adrenergic agonist clonidine. Biol Psychiatry 19:131–156.PubMedGoogle Scholar
  28. Siever LJ, Insel F, Uhde T (1981) Noradrenergic challenges in the affective disorders. J Clin Psychopharmacology 1:193–206.CrossRefGoogle Scholar
  29. Siever LJ, Uhde TW, Silberman EK, Jimerson DC, Aloi JA, Post RM, Murphy DL (1982a) Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls. Psychiatry Res 6:171–183.PubMedCrossRefGoogle Scholar
  30. Siever LJ, Uhde TW, Insel TR, Roy BF, Murphy DL (1982b) Growth hormone response to clonidine unchanged by chronic clorgyline treatment. Psychiatry Res 7:139–144.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • L. J. Siever
    • 1
  • E. F. Coccaro
    • 1
  • F. Adan
    • 1
  • R. C. Mohs
    • 1
  • K. L. Davis
    • 1
  1. 1.Bronx VA Medical CenterNew YorkUSA

Personalised recommendations